University of Chicago
uchicago.eduTotal trials
903
Active
236
Phase 3
27
Total enrollment
473,484
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 134 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ibuprofen 400 mg | — | — | — | — | — | 1 | |
| Darolutamide | — | — | — | — | — | 1 | |
| Physician choice Androgen Deprivation (Hormone) Therapy | — | — | — | — | — | 1 | |
| Norepinephrine | — | — | — | — | — | 1 | |
| Epinephrine | — | — | — | — | — | 1 | |
| Phenylephrine | — | — | — | — | — | 1 | |
| Vasopressin | — | — | — | — | — | 1 | |
| Experimental: Primary Cohort | — | — | — | — | — | 1 | |
| Aspirin 81 mg | — | — | — | — | — | 1 | |
| Dexamethasone | — | 18 | |||||
| Carfilzomib | — | — | — | 8 | |||
| Lenalidomide | — | — | — | — | 7 | ||
| Semaglutide | — | — | — | — | 2 | ||
| Sirolimus | — | — | — | 4 | |||
| Memantine | — | — | — | — | 3 | ||
| Bortezomib | — | — | — | — | — | 1 | |
| Cystine | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | 20 | |||
| Carboplatin | — | — | — | 21 | |||
| Paclitaxel | — | — | — | 20 | |||
| Docetaxel | — | — | — | 7 | |||
| Allogenic islet cells | — | — | — | — | 3 | ||
| Cisplatin | — | — | — | 12 | |||
| Methotrexate | — | — | — | — | 4 | ||
| Ipilimumab | — | — | — | — | 4 | ||
| Tamoxifen | — | — | — | — | — | 3 | |
| Letrozole | — | — | — | — | — | 3 | |
| Venetoclax | — | — | — | — | 3 | ||
| Vincristine | — | — | — | — | 3 | ||
| Rituximab | — | — | — | — | 3 | ||
| Decitabine | — | — | — | — | 2 | ||
| Cemiplimab | — | — | — | — | — | 2 | |
| cyclophosphamide | — | — | — | 7 | |||
| mifepristone | — | — | — | — | 5 | ||
| Etoposide | — | — | — | — | 4 | ||
| Capecitabine | — | — | — | — | 3 | ||
| nab-paclitaxel | — | — | — | — | 3 | ||
| Tocilizumab | — | — | — | — | — | 3 | |
| Enzalutamide | — | — | — | — | 3 | ||
| FEC | — | — | — | — | — | 2 |
94 more active programs hidden
Next readouts
- 2020-05-01
- 2022-04-01
- 2022-06-01
- 2022-12-21
- 2023-03-30
- 2025-06-26
- 2025-12-05
- 2026-04-12
- 2026-05
- 2026-06
Top conditions
- Breast Cancer22
- Head and Neck Cancer21
- Prostate Cancer21
- Substance-Related Disorders18
- Opioid-Related Disorders17
- Healthy16
- Sleep16
- Obesity12
Frequently asked questions about University of Chicago
- How many clinical trials does University of Chicago have on ClinicalTrials.gov?
- University of Chicago is listed as the lead sponsor on 903 clinical trials in ClinicalTrials.gov, 236 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Chicago's trials are in Phase 3?
- 27 of University of Chicago's trials are in Phase 3, spread across 134 active drug programs.
- What therapeutic areas does University of Chicago focus on?
- University of Chicago's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Head and Neck Cancer, Prostate Cancer, Substance-Related Disorders, Opioid-Related Disorders.
- When are University of Chicago's next clinical trial readouts?
- University of Chicago has 10 upcoming primary-completion readouts tracked here; the soonest is “Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer”, expected around 2020-05-01.